Daifalla, A., Tabl, A., ElFouly, M., Rezk, M. (2022). COMPARISON OF THE EFFECT OF RANIBIZUMAB AND TRIAMCINOLONE ACETONIDE IN DIABETIC MACULAR EDEMA WITH EPIRETINAL MEMBRANE IN PSEUDOPHAKIC PATIENTS. Benha Medical Journal, 39(Special issue (Ophthalmology)), 38-48. doi: 10.21608/bmfj.2021.80398.1425
Ahmed ElHussieny Daifalla; Ahmed AbdelShafy Tabl; Marwa AbdelKader ElFouly; Mohamed Mabrouk Rezk. "COMPARISON OF THE EFFECT OF RANIBIZUMAB AND TRIAMCINOLONE ACETONIDE IN DIABETIC MACULAR EDEMA WITH EPIRETINAL MEMBRANE IN PSEUDOPHAKIC PATIENTS". Benha Medical Journal, 39, Special issue (Ophthalmology), 2022, 38-48. doi: 10.21608/bmfj.2021.80398.1425
Daifalla, A., Tabl, A., ElFouly, M., Rezk, M. (2022). 'COMPARISON OF THE EFFECT OF RANIBIZUMAB AND TRIAMCINOLONE ACETONIDE IN DIABETIC MACULAR EDEMA WITH EPIRETINAL MEMBRANE IN PSEUDOPHAKIC PATIENTS', Benha Medical Journal, 39(Special issue (Ophthalmology)), pp. 38-48. doi: 10.21608/bmfj.2021.80398.1425
Daifalla, A., Tabl, A., ElFouly, M., Rezk, M. COMPARISON OF THE EFFECT OF RANIBIZUMAB AND TRIAMCINOLONE ACETONIDE IN DIABETIC MACULAR EDEMA WITH EPIRETINAL MEMBRANE IN PSEUDOPHAKIC PATIENTS. Benha Medical Journal, 2022; 39(Special issue (Ophthalmology)): 38-48. doi: 10.21608/bmfj.2021.80398.1425
COMPARISON OF THE EFFECT OF RANIBIZUMAB AND TRIAMCINOLONE ACETONIDE IN DIABETIC MACULAR EDEMA WITH EPIRETINAL MEMBRANE IN PSEUDOPHAKIC PATIENTS
1Ophthalmology Department, Faculty of Medicine, Benha University, Benha, Egypt
2Ophthalomology department, Research Institute of Ophthalmology, Giza, Egypt
3Ophthalomology department, Research Institute of Ophthalmology, Giza, Egypt.
Abstract
Background: Macular edema is considered the main cause of visual loss in diabetic retinopathy patients. Aim: The aim of this study is to compare the effectivness of Intravitreal Ranibizumab and Triamcinolone acetonide in management of diabetic macular edema with epiretinal membrane in pseudophakic patients. Methods: In this prospective observational study we compared the efficacy of Intravitreal Ranibizumab and Triamcinolone acetonide on 35 eyes of 28 pseudophakic patients with DME with ERM. BCVA , IOP and CMT were recorded to patients before injection and then at 1st , 4th , 8th and 12th week after injection. Results: BCVA improved from 0.5 (0.3–1.4) to reach 0.2 (0–0.9) LogMAR at 12th week postinjection in the Ranibizumab group and improved from 0.6 (0.5–1.6) to 0.4 (0.1–1.5) LogMAR at 12th week postinjection in TA group. IOP changed from baseline of 19.06±2.9 to 23.17±2.68 at 1st week reaching 19.56±1.72 at 12th week (p < /p>